 Quantitative MRI changes gadolinium-DTPA enhancement high-dose intravenous methylprednisolone multiple sclerosis patients definite multiple sclerosis total courses high-dose gram consecutive days intravenous methylprednisolone MRI brain gadolinium-DTPA treatment initial MRI total lesions unenhanced images treatment patients lesions enhancement visible unenhanced images new lesions second MRI Thus blood-brain-barrier integrity high-dose IV methylprednisolone clinical improvement lesions visible unenhanced images incomplete histologic recovery time second scan unenhanced MRI sufficient disease activity short term multiple sclerosis